Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial

Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015

(2017) David A. Watkins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structure–activity relationship of lipid core peptide-based Group A Streptococcus vaccine candidates

(2016) Amy Chan et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The inequitable burden of group A streptococcal diseases in Indigenous Australians

(2016) Philippa J May et al.   MEDICAL JOURNAL OF AUSTRALIA

Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate

(2016) Michael R. Batzloff et al.   Human Vaccines & Immunotherapeutics

Acute rheumatic fever and rheumatic heart disease

(2016) Jonathan R. Carapetis et al.   Nature Reviews Disease Primers

Novel platform technology for modular mucosal vaccine that protects against streptococcus

(2016) Mehfuz Zaman et al.   Scientific Reports

High burden of invasive group A streptococcal disease in the Northern Territory of Australia

(2015) R. BOYD et al.   EPIDEMIOLOGY AND INFECTION

The stark reality of rheumatic heart disease

(2015) J. R. Carapetis   EUROPEAN HEART JOURNAL

M-Protein Analysis of Streptococcus pyogenes Isolates Associated with Acute Rheumatic Fever in New Zealand

(2015) Deborah A. Williamson et al.   JOURNAL OF CLINICAL MICROBIOLOGY

A Synthetic M Protein Peptide Synergizes with a CXC Chemokine Protease To Induce Vaccine-Mediated Protection against Virulent Streptococcal Pyoderma and Bacteremia

(2015) Manisha Pandey et al.   JOURNAL OF IMMUNOLOGY

Effectiveness of Clindamycin and Intravenous Immunoglobulin, and Risk of Disease in Contacts, in Invasive Group A Streptococcal Infections

(2014) J. R. Carapetis et al.   CLINICAL INFECTIOUS DISEASES

The emm-Cluster Typing System for Group A Streptococcus Identifies Epidemiologic Similarities Across the Pacific Region

(2014) Noémie Baroux et al.   CLINICAL INFECTIOUS DISEASES

Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197

(2013) Ivette Caro-Aguilar et al.   Human Vaccines & Immunotherapeutics

Strategies in the development of vaccines to prevent infections with group A streptococcus

(2013) Michael F Good et al.   Human Vaccines & Immunotherapeutics

Cutting Edge Issues in Rheumatic Fever

(2011) Christopher Chang   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

An alternative technique for the induction of autoimmune valvulitis in a rat model of rheumatic heart disease

(2010) D. Gorton et al.   JOURNAL OF IMMUNOLOGICAL METHODS

The streptococcal M protein: a highly versatile molecule

(2010) Pierre R. Smeesters et al.   TRENDS IN MICROBIOLOGY

Systematic Review: Estimation of global burden of non-suppurative sequelae of upper respiratory tract infection: rheumatic fever and post-streptococcal glomerulonephritis

(2010) Stewart J. Jackson et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?

(2009) Pierre R Smeesters et al.   Expert Review of Vaccines

PDIA3, HSPA5 and vimentin, proteins identified by 2-DE in the valvular tissue, are the target antigens of peripheral and heart infiltrating T cells from chronic rheumatic heart disease patients

(2008) Kellen C. Faé et al.   JOURNAL OF AUTOIMMUNITY

Genetic diversity of Group A Streptococcus M protein: Implications for typing and vaccine development

(2008) Pierre R. Smeesters et al.   VACCINE